Enhancing anti-tumour efficacy with immunotherapy combinations.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
13 03 2021
13 03 2021
Historique:
received:
19
02
2020
revised:
11
08
2020
accepted:
24
08
2020
pubmed:
8
12
2020
medline:
12
11
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals for immune checkpoint inhibitors. However, many patients either do not respond or do not have durable clinical benefit. Thus, there is great interest in developing predictors of response to immunotherapy and rational combination therapies that can enhance efficacy by overcoming primary and acquired resistance. In this Review, we provide an assessment of immunotherapy response biomarkers that can identify patients who will benefit from monotherapy rather than from combinations. We review the rationale for combination therapy and different strategies, including combinations with chemotherapy, targeted therapy, radiation therapy, intratumoural therapies, other immunomodulators, and adaptive cell therapy, including chimeric antigen T-cell receptors and other novel T-cell receptor-based therapies. There are many combination partners in development; therefore, a programmatic approach is needed to develop a framework for biomarker-driven combination therapy selection.
Identifiants
pubmed: 33285141
pii: S0140-6736(20)32598-8
doi: 10.1016/S0140-6736(20)32598-8
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1010-1022Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.